• Topics

  • Formats

Organiser: Pharmaphorum

After spending 2024 in recovery mode, the biopharma industry is finally showing signs of growth, climbing back toward its pre-pandemic heights.

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth since the onset of the pandemic. The sector has taken time to recover from the subsequent slump, but are there signs that 2025 will be the year pharma finds its feet?

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?